121 related articles for article (PubMed ID: 12743423)
81. Immunohistochemical expression of caspase-3 as an adverse indicator of the clinical outcome in human breast cancer.
Nakopoulou L; Alexandrou P; Stefanaki K; Panayotopoulou E; Lazaris AC; Davaris PS
Pathobiology; 2001; 69(5):266-73. PubMed ID: 12107344
[TBL] [Abstract][Full Text] [Related]
82. Abnormal expression of MDM-2 in breast carcinomas.
Bueso-Ramos CE; Manshouri T; Haidar MA; Yang Y; McCown P; Ordonez N; Glassman A; Sneige N; Albitar M
Breast Cancer Res Treat; 1996; 37(2):179-88. PubMed ID: 8750585
[TBL] [Abstract][Full Text] [Related]
83. Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas.
Sierra A; Castellsague X; Escobedo A; Moreno A; Drudis T; Fabra A
Breast Cancer Res Treat; 1999 Mar; 54(1):39-45. PubMed ID: 10369079
[TBL] [Abstract][Full Text] [Related]
84. Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer.
Binder C; Marx D; Binder L; Schauer A; Hiddemann W
Ann Oncol; 1996 Feb; 7(2):129-33. PubMed ID: 8777167
[TBL] [Abstract][Full Text] [Related]
85. Expression of Bcl-2 and Bax in extrahepatic biliary tract carcinoma and dysplasia.
Li SM; Yao SK; Yamamura N; Nakamura T
World J Gastroenterol; 2003 Nov; 9(11):2579-82. PubMed ID: 14606101
[TBL] [Abstract][Full Text] [Related]
86. Microvessel density, p53 overexpression, and apoptosis in invasive breast carcinoma.
Gonzalez-Palacios F; Sancho M; Martinez JC; Bellas C
Mol Pathol; 1997 Dec; 50(6):304-9. PubMed ID: 9536280
[TBL] [Abstract][Full Text] [Related]
87. Relationships between proliferative activity and oncogene expression in human breast cancer.
Geuna M; Palestro G; Bianchi Malandrone L; Durando A; Demurtas A; Torchio B; Massobrio M
Ann N Y Acad Sci; 1996 Apr; 784():555-63. PubMed ID: 8651616
[No Abstract] [Full Text] [Related]
88. bcl-2 protein in invasive ductal breast carcinomas.
Hurlimann J; Larrinaga B; Vala DL
Virchows Arch; 1995; 426(2):163-8. PubMed ID: 7757287
[TBL] [Abstract][Full Text] [Related]
89. Differential expression of Bax and Bcl-2 in the assessment of cellular dynamics in fine-needle samples of primary breast carcinomas.
Maciorowski Z; Klijanienko J; Padoy E; Mosseri V; Diéras V; El-Naggar AK; Chevillard S; Vielh P
Cytometry; 2000 Oct; 42(5):264-9. PubMed ID: 11025483
[TBL] [Abstract][Full Text] [Related]
90. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?
Barnes DM; Dublin EA; Fisher CJ; Levison DA; Millis RR
Hum Pathol; 1993 May; 24(5):469-76. PubMed ID: 7684021
[TBL] [Abstract][Full Text] [Related]
91. The role of bcl-2 expression in breast carcinomas (Review).
Zhang GJ; Kimijima I; Tsuchiya A; Abe R
Oncol Rep; 1998; 5(5):1211-6. PubMed ID: 9683837
[TBL] [Abstract][Full Text] [Related]
92. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death.
Basu A; Haldar S
Mol Hum Reprod; 1998 Dec; 4(12):1099-109. PubMed ID: 9872359
[TBL] [Abstract][Full Text] [Related]
93. Comedonecrosis is an unfavorable marker in node-negative invasive breast carcinoma.
Yagata H; Harigaya K; Suzuki M; Nagashima T; Hashimoto H; Ishii G; Miyazaki M; Nakajima N; Mikata A
Pathol Int; 2003 Aug; 53(8):501-6. PubMed ID: 12895228
[TBL] [Abstract][Full Text] [Related]
94. Spindle cell carcinoma of the breast: a case report and an immunohistochemical study including p53 and Ki-67 expression.
Nakayama Y; Iwasaki H; Iwanaga S; Nakamura H; Shiroshita T; Kikuchi M; Jozaki H; Hashimoto M; Ikeda S
Pathol Int; 1997 Jun; 47(6):404-11. PubMed ID: 9211529
[TBL] [Abstract][Full Text] [Related]
95. Establishment and characterization of GSA-1, a human cell line highly susceptible to apoptosis after free-fall.
Nomura J; Himeda J; Chen Z; Sugaya S; Takahashi S; Kita K; Ichinose M; Suzuki N
J Radiat Res; 2002 Dec; 43 Suppl():S251-5. PubMed ID: 12793768
[TBL] [Abstract][Full Text] [Related]
96. Significance of Apoptosis and Apoptotic-Related Proteins, Bcl-2, and Bax in Primary Breast Cancer.
Wu J; Shao ZM; Shen ZZ; Lu JS; Han QX; Fontana JA; Barsky SH
Breast J; 2000 Jan; 6(1):44-52. PubMed ID: 11348334
[TBL] [Abstract][Full Text] [Related]
97. Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference?
Koukourakis MI; Giatromanolaki A; Galazios G; Sivridis E
Br J Cancer; 2003 Mar; 88(5):711-7. PubMed ID: 12618880
[TBL] [Abstract][Full Text] [Related]
98. The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis.
Yang P; Du CW; Kwan M; Liang SX; Zhang GJ
Sci Rep; 2013; 3():2246. PubMed ID: 23873310
[TBL] [Abstract][Full Text] [Related]
99. Identification of p53 and its isoforms in human breast carcinoma cells.
Milićević Z; Bajić V; Živković L; Kasapović J; Andjelković U; Spremo-Potparević B
ScientificWorldJournal; 2014; 2014():618698. PubMed ID: 24511294
[TBL] [Abstract][Full Text] [Related]
100. Expression of Apoptosis Related and Proliferative Proteins in Malignant Lympho-Proliferative Disorders.
Jairajpuri ZS; Ghai R; Saluja S; Kapur S; Bhowmik KT
Iran J Pathol; 2017; 12(3):231-240. PubMed ID: 29531548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
